Johnson & Johnson reported better-than-expected earnings and revenue for the third quarter, driven by strong sales in their medical devices and pharmaceutical divisions. Earnings per share were $2.66 adjusted versus the $2.52 expected, and revenue was $21.35 billion versus the $21.04 billion expected. J&J's attempt to resolve asbestos-related talc liabilities through a subsidiary's bankruptcy was rejected by a federal judge, though the company plans to appeal. The company has raised its full-year sales and profit guidance and expects higher sales and adjusted earnings per share in 2023.